VolitionRx Limited Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
VolitionRx Limited (VNRX) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$7.65 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2022-08-10
- VolitionRx Limited income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-06-30 was -$7.65M.
- VolitionRx Limited income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$7.63M.
- VolitionRx Limited income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2021-12-31 was -$8.04M.
- VolitionRx Limited income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2021-09-30 was -$7.14M.
- VolitionRx Limited income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was -$26.81M.
- VolitionRx Limited income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was -$20.35M.
- VolitionRx Limited income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2019 was -$16.10M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$7.65M 10-Q · filed 2022-08-10 | -$15.28M 10-Q · filed 2022-08-10 | -$23.32M derived: sum of 3 quarters · filed 2022-08-10 | -$30.46M derived: sum of 4 quarters · filed 2022-08-10 |
| 2022-03-31 | -$7.63M 10-Q · filed 2022-05-11 | -$15.67M derived: sum of 2 quarters · filed 2022-05-11 | -$22.81M derived: sum of 3 quarters · filed 2022-05-11 | -$28.33M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-12-31 | -$8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$15.17M derived: sum of 2 quarters · filed 2022-03-30 | -$20.70M derived: sum of 3 quarters · filed 2022-08-10 | -$26.81M 10-K · filed 2022-03-30 |
| 2021-09-30 | -$7.14M 10-Q · filed 2021-11-10 | -$12.66M derived: sum of 2 quarters · filed 2022-08-10 | -$18.78M 10-Q · filed 2021-11-10 | -$23.92M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-06-30 | -$5.53M 10-Q · filed 2022-08-10 | -$11.64M 10-Q · filed 2022-08-10 | -$16.78M derived: sum of 3 quarters · filed 2022-08-10 | -$21.11M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$6.12M 10-Q · filed 2022-05-11 | -$11.25M derived: sum of 2 quarters · filed 2022-05-11 | -$15.58M derived: sum of 3 quarters · filed 2022-05-11 | -$20.62M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$9.47M derived: sum of 2 quarters · filed 2022-03-30 | -$14.50M derived: sum of 3 quarters · filed 2022-03-30 | -$20.35M 10-K · filed 2022-03-30 |
| 2020-09-30 | -$4.33M 10-Q · filed 2021-11-10 | -$9.37M derived: sum of 2 quarters · filed 2021-11-10 | -$15.21M 10-Q · filed 2021-11-10 | -$18.77M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$5.04M 10-Q · filed 2021-08-11 | -$10.89M 10-Q · filed 2021-08-11 | -$14.44M derived: sum of 3 quarters · filed 2021-08-11 | -$18.63M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | -$5.85M 10-Q · filed 2021-05-11 | -$9.41M derived: sum of 2 quarters · filed 2021-05-11 | -$13.59M derived: sum of 3 quarters · filed 2021-05-11 | -$17.75M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | -$3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | -$7.74M derived: sum of 2 quarters · filed 2021-03-22 | -$11.90M derived: sum of 3 quarters · filed 2021-03-22 | -$16.10M 10-K · filed 2021-03-22 |
| 2019-09-30 | -$4.18M 10-Q · filed 2020-11-12 | -$8.34M derived: sum of 2 quarters · filed 2020-11-12 | -$12.54M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$4.16M 10-Q · filed 2020-08-13 | -$8.36M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | -$4.20M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |